Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
These conditions included pain disorders, such as low back pain (migraine patients, 10.3% vs non-migraine controls, 9.0%; P < 0.001) and fibromyalgia (6.6% vs 4.0%, respectively; P < 0.001); psychiatric disorders, such as anxiety (3.6% vs 1.9%; P < 0.001) and depression (3.2% vs 1.1%; P < 0.001); and cardiovascular risk factors, such as hypertension (20.2% vs 11.9%; P < 0.001) and dyslipidemia (28.1% vs 25.5%; P < 0.001; Table 4).ComorbiditiesVariable, n (%)Migraine patients (n = 26,545)Non-migraine controls* (n = 53,090)P†Psychiatric disorders Anxiety956 (3.6%)1009 (1.9%) < 0.001 Depression849 (3.2%)584 (1.1%) < 0.001Cardiovascular risk factors Obesity (BMI > 30 kg/m2)8335 (31.4%)20,280 (38.2%) < 0.001 Dyslipidemia7459 (28.1%)13,538 (25.5%) < 0.001 Essential hypertension5362 (20.2%)6318 (11.9%) < 0.001 Diabetes mellitus2708 (10.2%)7433 (14.0%) < 0.001 Pre-diabetes1141 (4.3%)3026 (5.7%) < 0.001Pain disorders Fibromyalgia1752 (6.6%)2124 (4.0%) < 0.001 Low back pain2734 (10.3%)4778 (9.0%) < 0.001 Disc lesions1274 (4.8%)2071 (3.9%) < 0.001Other Hypothyroidism2071 (7.8%)4300 (8.1%)0.249 Vitamin D deficiency1858 (7.0%)3769 (7.1%)0.616 Asthma1832 (6.9%)3238 (6.1%)0.238 Fatty liver1566 (5.9%)2973 (5.6%)0.223 Vitamin B12 deficiency1646 (6.2%)3292 (6.2%)0.912 Osteoporosis1566 (5.9%)3026 (5.7%)0.430 Iron deficiency anemia903 (3.4%)2283 (4.3%) < 0.001 Annual mortality (2018)70 (0.3%)186 (0.4%)0.717BMI body mass index*The non-migraine control group is matched to the migraine group based on gender, mean age (± 5 years), and primary clinic†Chi-square test for categorical variables/t test for normally distributed variables
Source: Comorbidities analysis. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this population-based, retrospective, observational cohort study, adult migraine patients were identified in the computerized database of the southern district of the Clalit Health Services HMO (total population, 0.75 million).
Source: Abstract.
We performed a population-based, retrospective, observational cohort study.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting
Cohort study · The Journal of Headache and Pain · 2022
Original publication title
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Understanding migraine epidemiology and its burden is crucial for planning health policies and interventions at the local level as well as at the global level. National policies in Israel rely on global estimations and not on local data since local epidemiologic studies had not previously been performed. In this study, we evaluated the epidemiology of migraine in the southern district of Israel using the electronic medical records database of the largest Israeli health maintenance organization (HMO).
Source: BackgroundAbstract: What methods does the paper describe?
In this population-based, retrospective, observational cohort study, adult migraine patients were identified in the computerized database of the southern district of the Clalit Health Services HMO (total population, 0.75 million). Patients were identified based on recorded diagnosis (International Classification of Diseases, Ninth Revision) and/or claims for specific anti-migraine medication (triptans) between 2000 and 2018. A 1:2 age-, gender-, and primary care clinic: matched control group was used for evaluation of comorbidities.
Source: MethodsAbstract: Results
In 2018, a total of 29,938 patients with migraine were identified out of 391,528 adult HMO members. Most of the patients were women (75.8%), and the mean ± standard deviation age at diagnosis was 36.94 ± 13.61 years. The overall prevalence of migraine (per 10,000) was 764.64 (7.65%), 1143.34 (11.43%) for women and 374.97 (3.75%) for men. The highest prevalence was observed in patients aged 50 to 60 years and 40 to 50 years (1143.98 [11.44%] and 1019.36 [10.19%], respectively), and the lowest prevalence was among patients aged 18 to 30 years and > 70 years (433.45 [4.33%] and 398.49 [3.98%], respectively).
Source: ResultsAbstract: Conclusions
This is the first large-scale epidemiologic study of migraine prevalence in Israel. Compared to international estimations, migraine appears to be underdiagnosed in the southern district of Israel.
Source: ConclusionsAuthors’ abstract
Background
Understanding migraine epidemiology and its burden is crucial for planning health policies and interventions at the local level as well as at the global level. National policies in Israel rely on global estimations and not on local data since local epidemiologic studies had not previously been performed. In this study, we evaluated the epidemiology of migraine in the southern district of Israel using the electronic medical records database of the largest Israeli health maintenance organization (HMO).
Methods
In this population-based, retrospective, observational cohort study, adult migraine patients were identified in the computerized database of the southern district of the Clalit Health Services HMO (total population, 0.75 million). Patients were identified based on recorded diagnosis (International Classification of Diseases, Ninth Revision) and/or claims for specific anti-migraine medication (triptans) between 2000 and 2018. A 1:2 age-, gender-, and primary care clinic: matched control group was used for evaluation of comorbidities.
Results
In 2018, a total of 29,938 patients with migraine were identified out of 391,528 adult HMO members. Most of the patients were women (75.8%), and the mean ± standard deviation age at diagnosis was 36.94 ± 13.61 years. The overall prevalence of migraine (per 10,000) was 764.64 (7.65%), 1143.34 (11.43%) for women and 374.97 (3.75%) for men. The highest prevalence was observed in patients aged 50 to 60 years and 40 to 50 years (1143.98 [11.44%] and 1019.36 [10.19%], respectively), and the lowest prevalence was among patients aged 18 to 30 years and > 70 years (433.45 [4.33%] and 398.49 [3.98%], respectively).
Conclusions
This is the first large-scale epidemiologic study of migraine prevalence in Israel. Compared to international estimations, migraine appears to be underdiagnosed in the southern district of Israel.
Publication and source details
Original title: Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting
Ido Peles; Mohnnad Asla; Mariya Abayev; Michal Gordon; Victor Novack; Rinat Ribalov; Tamar Lengil; Ron Maor; Mayera Elizur; Gal Ifergane
The Journal of Headache and Pain · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Teva PharmaceuticalsRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T21:34:07.744100+00:00
DOI: 10.1186/s10194-022-01513-w · PMC9749247